GLG LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

GLG LLC’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$682K	Hold	7,647	–	–	0.05%	300
2017 Q3	$712K	Sell	7,647 -711	-9%	-$62.8K	0.05%	335
2017 Q2	$759K	Sell	8,358 -669	-7%	-$60.9K	0.05%	347
2017 Q1	$792K	Sell	9,027 -21	-0.2%	-$1.87K	0.04%	375
2016 Q4	$750K	Sell	9,048 -14,395	-61%	-$1.24M	0.05%	330
2016 Q3	$2.17M	Buy	23,443 +3,702	+19%	+$349K	0.15%	151
2016 Q2	$1.54M	Sell	19,741 -10,114	-34%	-$860K	0.12%	198
2016 Q1	$2.46M	Buy	29,855 +16,795	+129%	+$1.37M	0.15%	174
2015 Q4	$1.37M	Buy	13,060 +336	+3%	+$35.1K	0.08%	249
2015 Q3	$1.34M	Sell	12,724 -43	-0.3%	-$5.74K	0.03%	372
2015 Q2	$1.75M	Sell	12,767 -226	-2%	-$28K	0.04%	373
2015 Q1	$1.62M	Buy	12,993 +1,360	+12%	+$144K	0.05%	360
2014 Q4	$1.05M	Hold	11,633	–	–	0.03%	439
2014 Q3	$839K	Hold	11,633	–	–	0.02%	528
2014 Q2	$724K	Hold	11,633	–	–	0.02%	568
2014 Q1	$793K	Buy	+11,633	New	+$857K	0.03%	522

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GLG LLC's BMRN Position: Q4 2017 in Review

GLG LLC held its BioMarin Pharmaceuticals (BMRN) position steady in Q4 2017 at 7,647 shares worth $682K. The position accounts for 0.05% of the portfolio, ranked #300.

GLG LLC first reported a position in BMRN in Q1 2014 and has held it in 16 quarters since. The position peaked at $2.46M in Q1 2016. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

GLG LLC held 7,647 shares of BioMarin Pharmaceuticals worth $682K as of Q4 2017.
GLG LLC left its BioMarin Pharmaceuticals share count unchanged in Q4 2017.
BioMarin Pharmaceuticals made up 0.05% of GLG LLC's portfolio in Q4 2017, its #300 holding.
GLG LLC first reported a position in BioMarin Pharmaceuticals in Q1 2014 and has held it in 16 quarters since.
GLG LLC's BioMarin Pharmaceuticals position peaked at $2.46M in Q1 2016.
438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on GLG LLC's 13F filing for Q4 2017, filed 14 Feb 2018.